Literature DB >> 2458178

Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro.

S Rockwell1, S R Keyes, A C Sartorelli.   

Abstract

Aerobic and hypoxic cultures of EMT6 mouse mammary tumor cells were used to study the effects of dicoumarol (DIC) on the cytotoxicity of mitomycin C (MC). DIC protected aerobic cells from MC toxicity, but sensitized hypoxic cells to the cytotoxic actions of this antibiotic. Survival curves for cells treated with 1.5 microM MC +/- 100 microM DIC for different periods of time under aerobic or hypoxic conditions showed that DIC acted as a dose-modifying agent, that is, an agent which changed the slopes, but not the shapes, of the MC survival curves. Experiments that examined the effects of the DIC concentration on the modulation of MC cytotoxicity revealed significant perturbations in MC toxicity with a DIC concentration of 100 microM and increased sensitization/protection with increasing levels of DIC. DIC altered the toxicity of MC only when it was present during exposure of the cells to MC. Treatment with DIC before or after (but not during) MC did not alter the amount of cytotoxicity. Addition of DIC to cell cultures seconds before the addition of MC was as effective as addition of DIC 30 min to 2 h before MC. Taken together, these findings suggest that DIC reversibly inhibits one or more enzymes involved in the activation and inactivation of MC, and that this modulation of the enzymatic processing of MC alters the cytotoxicity of the drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458178

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

Review 1.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

2.  Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo.

Authors:  S Rockwell; S R Keyes; A C Sartorelli
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells.

Authors:  S S Pan; S A Akman; G L Forrest; C Hipsher; R Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase.

Authors:  K Mikami; M Naito; T Ishiguro; H Yano; A Tomida; T Yamada; N Tanaka; T Shirakusa; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1998-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.